Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.58 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.58 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.58 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.58 |
| ▸ | CSNK1G3 | Q9Y6M4 | 4/20 | 0.58 |
| ▸ | GSK3B | P49841 | 4/20 | 0.58 |
| ▸ | FRK | P42685 | 3/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781591 | 0.96 | GRIA1 (0.62) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL7218478 | 0.83 | PTGS2 (0.60) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL7221055 | 0.83 | GRIA1 (0.54) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL9298472 | 0.83 | CSNK1D (0.58) | PRKD3MAPK9CSNK1A1CSNK1DPRKD2 | |
| SCHEMBL2068605 | 0.79 | TUBB4A (0.53) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL3521737 | 0.79 | TUBB4A (0.53) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL3522644 | 0.78 | PRKD3 (0.62) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL3522717 | 0.78 | CSNK1E (0.66) | PRKD3MAPK9CSNK1A1CSNK1DPRKD2 | |
| SCHEMBL3525119 | 0.77 | CSNK1D (0.52) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D | |
| SCHEMBL108805 | 0.77 | GRIA1 (0.45) | GRIA1PRKD3MAPK9CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4126878-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007028051-A2 | NOVEL IMIDAZO BASED HETEROCYCLES | ABBOTT LABORATORIES (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099925-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K19 | GRIA1 1729/4885PRKD3 365/4885MAPK9 189/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | GRIA1 2785/4885PRKD3 173/4885MAPK9 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.